NCT04807400 - Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support | Biotech Hunter

Enrollment

892

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions

Atherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease Risk EquivelentsElevated Low Density Lipoprotein Cholesterol

Interventions

DRUG

Inclisiran

Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection

BEHAVIORAL

Behavioural Support

Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.

DRUG

Background lipid lowering therapy

lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy

Trial Locations (17)

M33 4BR

Novartis Investigative Site, Sale

WA14 1PF

Novartis Investigative Site, Altrincham

M41 7WJ

Novartis Investigative Site, Davyhulme

M20 6BA

Novartis Investigative Site, Didsbury

M22 4DH

Novartis Investigative Site, Northenden

M33 2TB

Novartis Investigative Site, Sale

M27 8HP

Novartis Investigative Site, Swinton

M22 0EP

Novartis Investigative Site, Wythenshawe

M22 5RX

Novartis Investigative Site, Wythenshawe

OL9 0LH

Novartis Investigative Site, Chadderton

SK8 5LL

Novartis Investigative Site, Cheadle Hulme

M24 4DZ

Novartis Investigative Site, Greater Manchester

OL6 6EW

Novartis Investigative Site, Lancashire

M14 5NP

Novartis Investigative Site, Manchester

M14 6WP

Novartis Investigative Site, Manchester

M20 2RN

Novartis Investigative Site, Manchester

M33 2RH

Novartis Investigative Site, Manchester